Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the SEAQUAMAT trial, parenteral artesunate was shown to be associated with a considerably lower mortality than quinine, and is now the recommended treatment for severe malaria in low-transmission areas and in the second and third trimesters of pregnancy. A trial is underway to establish its role in African children. The development of artesunate suppositories may provide the means to treat patients with severe disease in remote rural settings, potentially buying the time needed to reach a health care facility. The increasing availability of basic intensive care facilities in developing countries also has the potential to further reduce mortality.

Original publication

DOI

10.1016/j.trstmh.2007.03.011

Type

Journal article

Journal

Trans R Soc Trop Med Hyg

Publication Date

07/2007

Volume

101

Pages

633 - 634

Keywords

Adult, Africa, Antimalarials, Artemisinins, Artesunate, Asia, Child, Child, Preschool, Female, Humans, Malaria, Falciparum, Pregnancy, Quinine, Randomized Controlled Trials as Topic, Sesquiterpenes, Suppositories